在乳腺癌中,由阿斯巴拉内酶通过ATR通路调节驱动的放射治疗耐药性
Macarena Morillo-Huesca1, Ignacio G López-Cepero1, Ryan Conesa-Bakkali1,2
1Centro Andaluz de Biología Molecular y Medicina Regenerativa - CABIMER, Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Sevilla, Universidad Pablo de Olavide, Américo Vespucio 24, Seville, 41092, Spain.
Journal of experimental & clinical cancer research : CR
|February 26, 2025
概括
阿斯巴拉金内酶 (AEP) 通过保持基因组稳定性和放射治疗耐药性来促进癌细胞的生存. 抑制AEP可能使瘤对化疗敏感,并作为治疗选择的预测生物标志物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 瘤耐药性是癌症治疗的一个重大挑战.
- 阿斯巴拉金内酶 (AEP) 的过度表达与固体瘤的预后不佳有关.
- 连接AEP与癌症患者生存率降低的机制尚未完全理解.
研究的目的:
- 确定新的AEP目标并阐明其在癌症中的作用.
- 研究AEP,基因组稳定性和乳腺癌中对放射治疗的耐药性之间的联系.
- 评估AEP/ATR轴作为预测生物标志物和治疗目标.
主要方法:
- 利用高通量蛋白质组学,细胞和分子生物学技术,以及临床乳腺癌数据.
- 采用免疫阻塞,qPCR,流细胞计,共聚焦显微镜和DNA修复试验.
- 在患者队伍上进行了体分析 (TCGA数据集) 和免疫光测定.
主要成果:
- AEP抑制ATR和PPP1R10,影响基因组稳定性和乳腺癌中的放射治疗耐药性.
- 降低ATR/PPP1R10水平与乳腺癌患者的预后不佳相关.
- 抑制AEP使乳腺癌细胞对化疗敏感,并将AEP/ATR轴确定为抗辐射患者的预测生物标志物.
结论:
- AEP/ATR/PPP1R10轴在乳腺癌的基因组稳定性和放射治疗耐药性方面发挥着至关重要的作用.
- 这项研究揭示了对瘤抵抗机制的新见解.
- 该AEP/ATR轴被验证为一个有前途的预测生物标志物和放射性抗性乳腺癌的治疗标.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K


